



Cancer Control Program Community Oncology Committee

200 First Street, SW
Rochester, MN 55905
P: 507-266-9202
F: 507-284-1803

www.allianceforclinicaltrialsinoncology.org

Daniel Anderson, MD
Peggy Kemeny, M.D.
Jon Strasser, M.D.
Co-Chairs

Agenda
Community Oncology Committee Leadership Meeting
November 5, 2016
11:30 AM – 2:30 PM CT
Room: Avedon C

Meeting available by teleconference: Dial 800-501-8979 Access Code: 2107872

Present	Committee Leadership Members:		
	Daniel Anderson, MD	Co-chair	Daniel.M.Anderson@HealthPartners.Com
	Peggy Kemeny, MD	Co-chair	kemenym@nychhc.org
	Jon Strasser, MD	Co-chair	jstrasser@christianacare.org
	Jan C. Buckner, MD	CCP Program Director	buckner.jan@mayo.edu
	Jacqueline M. Lafky, MS	CCP Program Manager	lafky.jacqueline@mayo.edu
	Deb Dickman	CCP Administrative Assistant	dickman.deborah@mayo.edu
	Neil Abrahams, MD	Pathology Representative	NAbrahams@mhs.net
	James N. Atkins, MD	Community BoD Representative	jnatkins@juno.com
	Bryan A. Faller, MD	CCDR Representative	baf3600@bjc.org
	Patrick Gavin, RPh	Patient Advocate Representative	pat@gavin-consulting.com
	Linda M. Gordon, MD	Imaging Representative	lindamgordon@gmail.com
	David Grisell, DO	Community BoD Representative	dgrisell@ghs.org
	Philip J. Stella, MD	Community BoD Representative	Philip.Stella@stjoeshealth.org
	Elizabeth White	CRP Representative	ecwhite@novanthealth.org
	Mary Beth Wilwerding, RN	Oncology Nursing Representative	mwilwerding@mvcc.cc

I. Welcome and Announcements (5 minutes)

II. Study Presentations (10-15 minutes each)

- A. Electronic Patient Reporting of Symptoms During Outpatient Cancer Treatment: A U.S. National Randomized Controlled Trial ("PRO-TECT")
Ethan Basch, MD
- B. CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography for Bulky Stage I/II Classical Hodgkin Lymphoma
Ann S. LaCasce, MD
- C. EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Alice Chen, MD

III. CCDR Activities (15 minutes each)

- A. Alliance CCDR Committee Updates
George Chang, MD
- B. NCI CCDR Updates
Kathleen Castro, RN, MS, AOCN

C. Q&A Session
Kathleen Castro, RN, MS, AOCN & George Chang, MD

IV. Dissemination and Implementation Committee (5 minutes)
Diana Dickson Witmer, MD, Sarah Blair, MD, Abigail Caudle, MD

V. NCORP Investigator Meeting Update (15 minutes)
Diane St. Germain, RN, MS

VI. Alliance Public Study Result Summaries Survey (10 minutes)
Deb Collyar

VII. Protocol Presentations (10 minutes each)

- A. 51101: A Randomized Phase II Trial of Myeloablative Versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Tracy Batchelor, MD
- B. A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ALCHEMIST
Jamie Chافت, MD
- C. A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid after Definite Radiation Therapy
Anuj Mahindra, MD
- D. A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy of Node Positive HER2 Negative Breast Cancer: The ABC Trial
Wendy Chen, MD
- E. EAQ152: Communication and Education in Tumor Profiling (COMET)
Mary L. O'Connor, MS
- F. A021302: Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Jon Strasser, MD on behalf of Manish Shah, MD

VIII. Study Chair and Community Co-Chair Survey Results (5-10 minutes)
Peggy Kemeny, MD and Jon Strasser, MD

IX. Other Business